Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
62.45 (1y: +47%)
Market Cap 215.43 B P/E(ttm) 20.60
Enterprise Value 234.8 B P/B 11.80
RHHBY- OTCPK (USA)
Roche Holding AG
  • Currently 1/5
Business Predictability Rank: 1-Star (On Watch)
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$62.45
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry		 vs
history
Cash to Debt 0.254
RHHBY's Cash to Debt is ranked lower than
56% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.63 vs. RHHBY: 0.254 )
RHHBY' s 10-Year Cash to Debt Range
Min: 0.25   Max: 5.08
Current: 0.25
0.25
5.08
Equity to Asset 0.258
RHHBY's Equity to Asset is ranked lower than
57% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. RHHBY: 0.258 )
RHHBY' s 10-Year Equity to Asset Range
Min: 0.1   Max: 0.59
Current: 0.26
0.1
0.59
F-Score: 7
Z-Score: 3.99
M-Score: -4.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry		 vs
history
Operating margin (%) 31.00
RHHBY's Operating margin (%) is ranked higher than
96% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.80 vs. RHHBY: 31.00 )
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.5   Max: 31.6
Current: 31
4.5
31.6
Net-margin (%) 21
RHHBY's Net-margin (%) is ranked higher than
92% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. RHHBY: 21 )
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.5   Max: 30.2
Current: 21
-13.5
30.2
ROE (%) 57
RHHBY's ROE (%) is ranked higher than
99% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.50 vs. RHHBY: 57 )
RHHBY' s 10-Year ROE (%) Range
Min: -19.3   Max: 105.7
Current: 57
-19.3
105.7
ROA (%) 14.7
RHHBY's ROA (%) is ranked higher than
96% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.40 vs. RHHBY: 14.7 )
RHHBY' s 10-Year ROA (%) Range
Min: -6.3   Max: 15.2
Current: 14.7
-6.3
15.2
ROC (Joel Greenblatt) (%) 64.10
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.40 vs. RHHBY: 64.10 )
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.3   Max: 66.2
Current: 64.1
6.3
66.2
Revenue Growth (%) -1.7
RHHBY's Revenue Growth (%) is ranked lower than
57% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. RHHBY: -1.7 )
RHHBY' s 10-Year Revenue Growth (%) Range
Min: -1.7   Max: 230.2
Current: -1.7
-1.7
230.2
EBITDA Growth (%) 2.6
RHHBY's EBITDA Growth (%) is ranked higher than
82% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. RHHBY: 2.6 )
RHHBY' s 10-Year EBITDA Growth (%) Range
Min: -0.9   Max: 172.1
Current: 2.6
-0.9
172.1
EPS Growth (%) 5.5
RHHBY's EPS Growth (%) is ranked higher than
84% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. RHHBY: 5.5 )
RHHBY' s 10-Year EPS Growth (%) Range
Min: -2.4   Max: 204.2
Current: 5.5
-2.4
204.2
ยป RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

RHHBY Guru Trades in Q2 2012

Vanguard Health Care Fund 4,273,977 sh (+543.36%)
Tweedy Browne 82,130 sh (unchged)
First Pacific Advisors Sold Out
Ken Fisher 154,713 sh (-24.26%)
» More
Q3 2012

RHHBY Guru Trades in Q3 2012

Vanguard Health Care Fund 4,273,977 sh (unchged)
Ken Fisher 143,473 sh (-7.27%)
Tweedy Browne 62,164 sh (-24.31%)
» More
Q4 2012

RHHBY Guru Trades in Q4 2012

Tweedy Browne 60,274 sh (-3.04%)
Ken Fisher 122,230 sh (-14.81%)
» More
Q1 2013

RHHBY Guru Trades in Q1 2013

Ken Fisher 897,861 sh (+634.57%)
Tweedy Browne 60,274 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Tweedy Browne 2012-09-30 Reduce -24.31%0.03%$41.9 - $48.14 $ 62.4539%62164
Vanguard Health Care Fund 2012-06-30 Add 543.36%2.96%$38.94 - $46.28 $ 62.4548%4273977
Tweedy Browne 2012-03-31 Reduce -22.19%0.04%$43.1 - $44.33 $ 62.4556%82130
Premium More recent guru trades are included for Premium Members only!!
ยป Financial Charts

Peter Lynch Chart

Top Ranked Articles about Roche Holding AG

How Faithful Are You?
March 31, 2013
Checklists are an important tool for value investors. They protect us against our inherent mental shortcuts/biases and a need to โ€œjump to conclusions.โ€ They also make sure that we have thought about a pre-decided set of downsides and are not fitting the data to derive a particular conclusion. This last point is best explained by a story.[quote] Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 20.60
RHHBY's P/E(ttm) is ranked higher than
73% of the 497 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.30 vs. RHHBY: 20.60 )
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.05   Max: 52.91
Current: 20.6
13.05
52.91
P/B 11.80
RHHBY's P/B is ranked lower than
66% of the 621 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.46 vs. RHHBY: 11.80 )
RHHBY' s 10-Year P/B Range
Min: 2.63   Max: 22.11
Current: 11.8
2.63
22.11
P/S 4.33
RHHBY's P/S is ranked higher than
54% of the 654 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.68 vs. RHHBY: 4.33 )
RHHBY' s 10-Year P/S Range
Min: 2.38   Max: 6.08
Current: 4.33
2.38
6.08
PFCF 15.60
RHHBY's PFCF is ranked higher than
84% of the 399 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.96 vs. RHHBY: 15.60 )
RHHBY' s 10-Year PFCF Range
Min: 8.71   Max: 56.03
Current: 15.6
8.71
56.03
EV-to-EBIT 15.4
RHHBY's EV-to-EBIT is ranked higher than
75% of the 496 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.43 vs. RHHBY: 15.4 )
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.2   Max: 118.9
Current: 15.4
7.2
118.9
PEG 25.8
RHHBY's PEG is ranked lower than
60% of the 263 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.22 vs. RHHBY: 25.8 )
RHHBY' s 10-Year PEG Range
Min: 0.11   Max: 29.86
Current: 25.8
0.11
29.86
Shiller P/E 20.9
RHHBY's Shiller P/E is ranked lower than
100% of the Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: vs. RHHBY: 20.9 )
RHHBY' s 10-Year Shiller P/E Range
Min: 13.46   Max: 117.89
Current: 20.9
13.46
117.89

Dividend & Buy Back

vs
industry		 vs
history
Dividend Yield 2.95
RHHBY's Dividend Yield is ranked higher than
90% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.37 vs. RHHBY: 2.95 )
RHHBY' s 10-Year Dividend Yield Range
Min: 0.72   Max: 4.55
Current: 2.95
0.72
4.55
Dividend Payout 0.5954
RHHBY's Dividend Payout is ranked higher than
52% of the 338 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.50 vs. RHHBY: 0.5954 )
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.59
Current: 0.6
0.21
0.59
Dividend growth (3y) -3
RHHBY's Dividend growth (3y) is ranked lower than
63% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. RHHBY: -3 )
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 19.8
Current: -3
0
19.8
Yield on cost (5-Year) 2.67
RHHBY's Yield on cost (5-Year) is ranked higher than
86% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.29 vs. RHHBY: 2.67 )
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 0.64   Max: 4.05
Current: 2.67
0.64
4.05
Share Buyback Rate 0.1
RHHBY's Share Buyback Rate is ranked higher than
92% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. RHHBY: 0.1 )
RHHBY' s 10-Year Share Buyback Rate Range
Min: 68.6   Max: -0.6
Current: 0.1

Valuation & Return

vs
industry		 vs
history
Price/Net Current Asset Value 71
RHHBY's Price/Net Current Asset Value is ranked lower than
61% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.20 vs. RHHBY: 71 )
RHHBY' s 10-Year Price/Net Current Asset Value Range
Min: 12.9   Max: 58.8
Current: 71
12.9
58.8
Price/Tangible Book 39
RHHBY's Price/Tangible Book is ranked lower than
71% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. RHHBY: 39 )
RHHBY' s 10-Year Price/Tangible Book Range
Min: 5.2   Max: 31.7
Current: 39
5.2
31.7
Price/DCF (Projected) 1.7
RHHBY's Price/DCF (Projected) is ranked higher than
75% of the 283 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.80 vs. RHHBY: 1.7 )
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.1   Max: 3.6
Current: 1.7
1.1
3.6
Price/Median PS Value 1.1
RHHBY's Price/Median PS Value is ranked higher than
65% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.10 vs. RHHBY: 1.1 )
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 1.3
Current: 1.1
0.6
1.3
Price/Graham Number 6.2
RHHBY's Price/Graham Number is ranked lower than
66% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. RHHBY: 6.2 )
RHHBY' s 10-Year Price/Graham Number Range
Min: 1.8   Max: 5
Current: 6.2
1.8
5
Earnings Yield (Greenblatt) 6.50
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
81% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. RHHBY: 6.50 )
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 13.9
Current: 6.5
0.8
13.9
Forward Rate of Return (Yacktman) 5.64
RHHBY's Forward Rate of Return (Yacktman) is ranked higher than
85% of the 709 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. RHHBY: 5.64 )
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 6   Max: 199.6
Current: 5.64
6
199.6

Business Description

Roche Holding produces pharmaceuticals, vitamins, fine chemicals, diagnostic products, fragrances, and flavors. Its pharmaceuticals, which account for the majority of the company's total sales, treat infectious, cardiovascular, inflammatory, and autoimmune diseases, among others. Its Rocephin ranks as the best-selling injectable antibiotic worldwide.
Company Website
Industry: Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, NVS, ABT
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany
ยป More Articles for OTCPK:RHHBY

Headlines

Articles On GuruFocus.com
How Faithful Are You? Mar 31 2013 
Value Idea Update: Roche (RHHBY) Mar 21 2013 
comment on RHHBY Feb 24 2013 
Tweedy Browne Q3 Letter Nov 01 2012 
52-Week High Companies: PRGO, NOC, RHHBY, NXY, PFE Oct 15 2012 
Core holdings from my portfolio Sep 02 2012 
Roche Is Paying Down Its Debt Apr 27 2012 
Abbott: A Strong Play In 2012 Mar 31 2012 
Investing Mistakes and What Not to Do (End 2009-Mid 2010) Jan 27 2012 
Tweedy, Browne Q4 Letter - All Funds Up, Named 2011 Int'l-Stock Fund Manager of the Year Jan 26 2012 

More From Our Partners
PDL BioPharma Guides Higher 2Q Royalties - Analyst Blog Jun 13 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK